Affordable Access

deepdyve-link
Publisher Website

Mitigating placental injuries through up-regulating DAF in experimental APS mice: new mechanism of progesterone.

Authors
  • Zhang, Y1
  • Jin, S1, 2
  • 1 Department of Traditional Chinese Medicine, Maternal and Child Health Hospital of Hubei Province, Hubei, China. , (China)
  • 2 First Clinical Medical College, Hubei University of Chinese Medicine, Hubei, China. , (China)
Type
Published Article
Journal
Clinical & Experimental Immunology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Sep 01, 2019
Volume
197
Issue
3
Pages
376–386
Identifiers
DOI: 10.1111/cei.13313
PMID: 31091357
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Anti-phospholipid syndrome (APS) is characterized by recurrent pathological pregnancy, arterial or venous thrombosis in the presence of anti-phospholipid antibody (aPL). Complement activation is recognized as an intermediate link leading to placental thrombosis and placental inflammation in APS model mice. Decay accelerating factor (DAF, CD55), MAC-inhibitory protein (MAC-IP, CD59) and membrane co-factor protein (MCP, CD46) are important complement inhibitory proteins (CIPs) highly expressed in normal placenta to curb excessive complement activation and its mediated injuries. Anti-β2 glycoprotein I (anti-β2GPI) antibody is an important aPL. We found that placental DAF and CD46 decreased in β2GPI passively immunized APS model mice, accompanied by C3 deposition, neutrophil infiltration and increased proinflammatory cytokine levels detected in its placenta. Progesterone supplement can up-regulate DAF but not CD46 expression, curb C3 activation and decrease proinflammatory cytokines levels to reduce fetal loss frequency. Progesterone receptor antagonist (mifepristone) or knock-down DAF with specific siRNA, above the protective effects of progesterone, were significantly weakened. Another sex hormone, oestrogen, has no significant effect on placental DAF and C3 contents and fetal loss frequency in the APS mice model. This may be an important mechanism by which progesterone induces maternal-fetal immune tolerance. At the same time, it may provide evidence for the use of progesterone in APS abortion patients. © 2019 British Society for Immunology.

Report this publication

Statistics

Seen <100 times